Therapeutic potential of microRNA modulation in pulmonary arterial hypertension

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 331-340

  Meloche, Jolyane ^a   Paulin, Roxane ^b   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biomarker; MicroRNA; Molecular biology; Pulmonary arterial hypertension; Remodeling; Therapeutic target

Indexed keywords

ANTAGOMIR 20A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MICRORNA 126; MICRORNA 138; MICRORNA 143; MICRORNA 145; MICRORNA 17; MICRORNA 195; MICRORNA 204; MICRORNA 206; MICRORNA 20A; MICRORNA 21; MICRORNA 210; MICRORNA 22; MICRORNA 27B; MICRORNA 302B; MICRORNA 30C; MICRORNA 328; MICRORNA 34A; MICRORNA 367; MICRORNA 450A; MICRORNA 451; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC INTERMITTENT HYPOXIA; DOWN REGULATION; ESSENTIAL HYPERTENSION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY MUSCLE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG EFFECTS; GENETICS; HYPERTENSION, PULMONARY; PATHOLOGY; PULMONARY ARTERY; SMOOTH MUSCLE CELL;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY;

EID: 84937146536     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990010     Document Type: Article

References (108)

1. [1] Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113(6): 673-6.
2. [2] Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310(5755): 1817-21.
3. [3] Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev 2005; 15(2): 200-5.
4. [4] Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 2009; 27(6): 549-55.
5. [5] Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005; 37(7): 766-70.
6. [6] Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120(1): 21-4.
7. [7] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
8. [8] John B, Sander C, Marks DS. Prediction of human microRNA targets. Methods Mol Biol 2006; 342: 101-13.
9. [9] Warner DR, Bhattacherjee V, Yin X, et al. Functional interaction between Smad, CREB binding protein, and p68 RNA helicase. Biochem Biophys Res Commun 2004; 324(1): 70-6.
10. [10] Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007; 67(5): 2345-50.
11. [11] Zhang C. MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle 2009; 8(21): 3469-73.
12. [12] Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009; 13(4): 778-89.
13. [13] Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010; 30(4): 716-23.
14. [14] Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007; 100(11): 1579-88.
15. [15] Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12(9): 735-9.
16. [16] Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105(2): 158-66.
17. [17] Wang YS, Wang HY, Liao YC, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res 2012; 95(4): 517-26.
18. [18] Li D, Zhao Y, Liu C, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17(7): 1722-30.
19. [19] Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol 2011; 226(10): 2535-42.
20. [20] Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50(1): 113-21.
21. [21] Zhang QQ, Xu H, Huang MB, et al. MicroRNA-195 plays a tumorsuppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neurooncology 2012; 14(3): 278-87.
22. [22] Anand S, Cheresh DA. Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. Genes Cancer 2011; 2(12): 1134-8.
23. [23] Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111-7.
24. [24] Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1 Suppl): S55-66.
25. [25] Voelkel NF, Tuder RM. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pulm Pharmacol Ther 1997; 10(5-6): 231-41.
26. [26] Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122(2): 156-63.
27. [27] Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122(2): 164-72.
28. [28] Dromparis P, Sutendra G, Michelakis ED. The role of mitochondria in pulmonary vascular remodeling. J Mol Med (Berl) 2010; 88(10): 1003-10.
29. [29] Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121(18): 2045-66.
30. [30] Davis-Dusenbery BN, Wu C, Hata A. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 2011; 31(11): 2370-7.
31. [31] Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67(18): 8433-8.
32. [32] He M, Wang QY, Yin QQ, et al. HIF-1alpha downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ 2013; 20(3): 408-18.
33. [33] Paulin R, Courboulin A, Meloche J, et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11): 1205-15.
34. [34] Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Nat Acad Sci USA 2007; 104(27): 11418-23.
35. [35] Yan J, Shen Y, Wang Y, Li BB. Increased expression of hypoxiainducible factor-1alpha in proliferating neointimal lesions in a rat model of pulmonary arterial hypertension. Am J Med Sci 2012.
36. [36] Zhang R, Wu Y, Zhao M, et al. Role of HIF-1alpha in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2009; 297(4): L631-40.
37. [37] Brock M, Samillan VJ, Trenkmann M, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J 2014; 35(45): 3203-11.
38. [38] Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples Circ Res 2012; 111(3): 290-300.
39. [39] Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011; 208(3): 535-48.
40. [40] Drake KM, Zygmunt D, Mavrakis L, et al. Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med 2011; 184(12): 1400-8.
41. [41] Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol 2012; 303(8): L682-91.
42. [42] Jalali S, Ramanathan GK, Parthasarathy PT, et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PloS One 2012; 7(10): e46808.
43. [43] Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. American journal of physiology Lung Cell Mol Physiol 2010; 299(6): L861-71.
44. [44] Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl 2011; (172): 15-34.
45. [45] Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2): 427-38.
46. [46] Jukic DM, Rao UN, Kelly L, et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8: 27.
47. [47] Turner DP, Findlay VJ, Moussa O, et al. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 2011; 71(16): 1723-35.
48. [48] Ryan J, Tivnan A, Fay J, et al. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 2012; 107(6): 967-76.
49. [49] Chen LH, Tsai KL, Chen YW, et al. MicroRNA as a novel modulator in head and neck squamous carcinoma. J Oncol 2010; 2010: 135632.
50. [50] Chen X, Yan Q, Li S, et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett 2012; 314(1): 41-53.
51. [51] Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68(13): 5004-8.
52. [52] Song G, Zhang Y, Wang L. MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem 2009; 284(46): 31921-7.
53. [53] Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med 2011; 89(11): 1089-101.
54. [54] Li X, Zhang X, Leathers R, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med 2009; 15(11): 1289-97.
55. [55] Thistlethwaite PA, Li X, Zhang X. Notch signaling in pulmonary hypertension. Adv Exp Med Biol 2010; 661: 279-98.
56. [56] Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104(2): 236-44, 28p following 44.
57. [57] Tada Y, Majka S, Carr M, et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. American journal of physiology Lung Cell Mol Physiol 2007; 292(6): L1556-63.
58. [58] Zakrzewicz A, Hecker M, Marsh LM, et al. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. Circulation 2007; 115(23): 2957-68.
59. [59] Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factorbeta(1) and bone morphogenetic proteins. Circulation 2001; 104(7): 790-5.
60. [60] Southwood M, Jeffery TK, Yang X, et al. Regulation of bone morphogenetic protein signalling in human pulmonary vascular development. J Pathol 2008; 214(1): 85-95.
61. [61] Thomas M, Docx C, Holmes AM, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. The Am J Pathol 2009; 174(2): 380-9.
62. [62] Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005; 96(10): 1053-63.
63. [63] Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009; 119(4): 566-76.
64. [64] Shintani M, Yagi H, Nakayama T, Saji T, Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009; 46(5): 331-7.
65. [65] Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454(7200): 56-61.
66. [66] Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010; 39(3): 373-84.
67. [67] Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 2009; 104(10): 1184-91.
68. [68] Wong WK, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2005; 33(5): 438-46.
69. [69] Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circul Physiol 2011; 301(5): H1798-809.
70. [70] Pullamsetti SS, Doebele C, Fischer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012; 185(4): 409-19.
71. [71] Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107(4): 611-8.
72. [72] Parikh VN, Jin RC, Rabello S, et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012; 125(12): 1520-32.
73. [73] Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006; 113(22): 2630-41.
74. [74] Mizuno S, Bogaard HJ, Kraskauskas D, et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am J Physiol Lung Cell Mol Physiol 2011; 300(5): L753-61.
75. [75] Bernardo BC, Gao XM, Winbanks CE, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci USA 2012; 109(43): 17615-20.
76. [76] Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 2009; 35(6): 856-67.
77. [77] Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009; 284(50): 35134-43.
78. [78] Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Thera 2008; 7(2): 255-64.
79. [79] Chen Z, Li Y, Zhang H, Huang P, Luthra R. Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene 2010; 29(30): 4362-8.
80. [80] Guo L, Qiu Z, Wei L, et al. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-alpha1C. Hypertension 2012; 59(5): 1006-13.
81. [81] Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460(7256): 705-10.
82. [82] Yamaguchi S, Yamahara K, Homma K, et al. The role of microRNA-145 in human embryonic stem cell differentiation into vascular cells. Atherosclerosis 2011; 219(2): 468-74.
83. [83] Courboulin A, Tremblay VL, Barrier M, et al. Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011; 12: 128.
84. [84] Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155(2): 411-9.
85. [85] Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22(3): 405-18.
86. [86] Jonigk D, Golpon H, Bockmeyer CL, et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011; 179(1): 167-79.
87. [87] Bockmeyer CL, Maegel L, Janciauskiene S, et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012; 31(7): 764-72.
88. [88] Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res 2009; 10: 95.
89. [89] Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009; 66(2): 169-75.
90. [90] Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 2010; 464(7292): 1196-200.
91. [91] D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115(5): 343-9.
92. [92] Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994; 89(4): 1733-44.
93. [93] Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest 2011;141(4):935-43.
94. [94] Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008; 451(7181): 943-8.
95. [95] McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Srivastava D, Olson EN. The Hand1 and Hand2 transcription factors regulate expansion of the embryonic cardiac ventricles in a gene dosage-dependent manner. Development 2005; 132(1): 189-201.
96. [96] Drake JI, Bogaard HJ, Mizuno S, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011; 45(6): 1239-47.
97. [97] Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446(7134): 444-8.
98. [98] Reddy S, Zhao M, Hu DQ, et al. Dynamic microRNA Expression During the Transition from Right Ventricular Hypertrophy to Failure. Physiol Genomics 2012.
99. [99] van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103(48): 18255-60.
100. [100] Wang N, Zhou Z, Liao X, Zhang T. Role of microRNAs in cardiac hypertrophy and heart failure. IUBMB Life 2009; 61(6): 566-71.
101. [101] Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170(6): 1831-40.
102. [102] Urashima T, Zhao M, Wagner R, et al. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 2008; 295(3): H1351-H68.
103. [103] Reddy S, Zhao M, Hu DQ, et al. Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genomics. 2012; 44(10): 562-75.
104. [104] Globits S, Burghuber OC, Koller J, et al. Effect of lung transplantation on right and left ventricular volumes and function measured by magnetic resonance imaging. Am J Respir Criti Care Med 1994; 149(4 Pt 1): 1000-4.
105. [105] Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Review molecular diagnostics 2010; 10(3): 297-308.
106. [106] Qi R, Weiland M, Gao XH, Zhou L, Mi QS. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer. Hepatology 2012; 55(5): 1640-2; author reply 2-3.
107. [107] Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2012; 54(5): 1767-76.
108. [108] Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18(10): 997-1006.